Clinical Trial


30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks


Brief description

The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30 mg, or 45 mg, administered orally once daily), and linagliptin (5 mg, administered orally once daily). In addition, durability of treatment effect and safety under chronic treatment conditions will be investigated.

Keywords

  •   Diabetes Mellitus, Type 2

Sponsored By

Boehringer Ingelheim

Unique Study ID

NCT01183013

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Sanofi
B15 2GW, Birmingham, United Kingdom
Distance from Current Trial is 0 miles

Jereme D Wilroy, PhD

University of Alabama at Birmingham
35209, Birmingham, Alabama, United States
Distance from Current Trial is 0 miles

Ansar Mahmood

University of Aberdeen
B15 2TH, Birmingham, United Kingdom
Distance from Current Trial is 0 miles
View All